Design of enhanced agonists through the use of a new virtual screening method: Application to peptides that bind class I major histocompatibility complex (MHC) molecules

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Protein Science

• Publication date

  2005-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1110/ps.051351605PMID 16046628PMCID PMC2279318
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Crystal Structure of 6,7-Dihydro-5a,7a,13,14-tetraaza-pentaphene-5,8-dione

  2019cited by this paper
• Pillars Article: Structure of the human class I histocompatibility antigen, HLA-A2.

  2005cited by this paper
• A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1

  2004cited by this paper
• MHC ligands and peptide motifs: first listing

  2004cited by this paper
• Structural mining: self-consistent design on flexible protein-peptide docking and transferable binding affinity potential.

  2004cited by this paper
• Peptide Based Vaccine Design for Cancer Immunotherapy

  2004cited by this paper
• Predicting peptide binding to MHC pockets via molecular modeling, implicit solvation, and global optimization

  2004cited by this paper
• Conformational flexibility of the MHC class I alpha1-alpha2 domain in peptide bound and free states: a molecular dynamics simulation study.

  2004cited by this paper
• Modeling the structure of bound peptide ligands to major histocompatibility complex

  2004cited by this paper
• Application of support vector machines for T-cell epitopes prediction

  2003cited by this paper
• Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach.

  2003cited by this paper
• Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors.

  2002cited by this paper
• Structural Comparison of Allogeneic and Syngeneic T Cell Receptor–Peptide-Major Histocompatibility Complex Complexes

  2002influential reference
• Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design.

  2002cited by this paper
• Clinical cancer vaccine trials.

  2002cited by this paper
• Prediction of promiscuous peptides that bind HLA class I molecules

  2002cited by this paper
• Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

  2002cited by this paper
• Structure‐based ligand design by a build‐up approach and genetic algorithm search in conformational space

  2001cited by this paper
• Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes1

  2001cited by this paper
• The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.

  2001cited by this paper
• Isolation of a New Melanoma Antigen, MART-2, Containing a Mutated Epitope Recognized by Autologous Tumor-Infiltrating T Lymphocytes1

  2001cited by this paper
• Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1

  2000cited by this paper
• Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

  2000cited by this paper
• Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.

  1999cited by this paper
• SYFPEITHI: database for MHC ligands and peptide motifs

  1999cited by this paper
• Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

  1999cited by this paper
• Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins.

  1999cited by this paper
• Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

  1999cited by this paper
• Application of an artificial neural network to predict specific class I MHC binding peptide sequences

  1998cited by this paper
• Peptide selection by an MHC H-2Kb class I molecule devoid of the central anchor ("C") pocket.

  1998cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• Predicting peptides that bind to MHC molecules using supervised learning of hidden markov models

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.

  1998cited by this paper
• Use of complete eluted peptide sequence data from HLA-DR and -DQ molecules to predict T cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection.

  1998cited by this paper
• MHC Ligands and Peptide Motifs

  1998cited by this paper
• Two complementary methods for predicting peptides binding major histocompatibility complex molecules.

  1997cited by this paper
• Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

  1997cited by this paper
• Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens

  1996cited by this paper
• Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo

  1996cited by this paper
• Free energy mapping of class I MHC molecules and structural determination of bound peptides

  1996cited by this paper
• Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo

  1996cited by this paper
• Oncogenic proteins as tumor antigens.

  1996cited by this paper
• Peptide docking using dynamic programming

  1996cited by this paper
• Flexible docking of peptides to class I major-histocompatibility-complex receptors.

  1995cited by this paper
• Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

  1995cited by this paper
• Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb.

  1994cited by this paper
• Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules.

  1994cited by this paper
• Toward computational determination of peptide‐receptor structure

  1993cited by this paper
• X-PLOR Version 3.1: A System for X-ray Crystallography and NMR

  1992influential reference
• Thermal stability comparison of purified empty and peptide-filled forms of a class I MHC molecule.

  1992cited by this paper
• Monte Carlo docking of oligopeptides to proteins

  1992cited by this paper
• Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

  1991cited by this paper
• Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution.

  1991cited by this paper
• Electrostatic effects in proteins: comparison of dielectric and charge models.

  1991cited by this paper
• Structure of the human class I histocompatibility antigen, HLA-A2

  1987cited by this paper

• Algorithm-supported, mass and sequence diversity-oriented random peptide library design

  2019cites this paper
• Identification of B and T cell epitope based peptide vaccine from IGF-1 receptor in breast cancer.

  2017cites this paper
• In silico designing breast cancer peptide vaccine for binding to MHC class I and II: A molecular docking study

  2016cites this paper
• DockTope: a Web-based tool for automated pMHC-I modelling

  2015cites this paper
• Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes

  2015cites this paper
• Anti-diarrheal constituents of Alpinia oxyphylla.

  2013cites this paper
• Estudo in silico das bases moleculares responsáveis pela reatividade cruzada entre epitopos virais restritos ao alelo HLA-A*02:01

  2011cites this paper
• Structural Allele-Specific Patterns Adopted by Epitopes in the MHC-I Cleft and Reconstruction of MHC:peptide Complexes to Cross-Reactivity Assessment

  2010cites this paper
• Prediction of structural stability of short beta-hairpin peptides by molecular dynamics and knowledge-based potentials

  2008cites this paper
• Ligand design by a combinatorial approach based on modeling and experiment: application to HLA-DR4

  2007cites this paper